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Abstract
Background: The cyclin-dependent kinase (CDK) inhibitor p27
Kip1 is downregulated in a majority of human cancers
due to ectopic proteolysis by the ubiquitin-proteasome pathway. The expression of p27 is subject to multiple
mechanisms of control involving several transcription factors, kinase pathways and at least three different ubiquitin
ligases (SCF
SKP2, KPC, Pirh2), which regulate p27 transcription, translation, protein stability and subcellular
localization. Using a chemical genetics approach, we have asked whether this control network can be modulated
by small molecules such that p27 protein expression is restored in cancer cells.
Results: We developed a cell-based assay for measuring the levels of endogenous nuclear p27 in a high
throughput screening format employing LNCaP prostate cancer cells engineered to overexpress SKP2. The assay
platform was optimized to Z’ factors of 0.48 - 0.6 and piloted by screening a total of 7368 chemical compounds.
During the course of this work, we discovered two small molecules of previously unknown biological activity,
SMIP001 and SMIP004, which increase the nuclear level of p27 at low micromolar concentrations. SMIPs (small
molecule inhibitors of p27 depletion) also upregulate p21
Cip1, inhibit cellular CDK2 activity, induce G1 delay, inhibit
colony formation in soft agar and exhibit preferential cytotoxicity in LNCaP cells relative to normal human
fibroblasts. Unlike SMIP001, SMIP004 was found to downregulate SKP2 and to stabilize p27, although neither SMIP
is a proteasome inhibitor. Whereas the screening endpoint - nuclear p27 - was robustly modulated by the
compounds, SMIP-mediated cell cycle arrest and apoptosis were not strictly dependent on p27 and p21 - a finding
that is explained by parallel inhibitory effects of SMIPs on positive cell cycle regulators, including cyclins E and A,
and CDK4.
Conclusions: Our data provide proof-of-principle that the screening platform we developed, using endogenous
nuclear p27 as an endpoint, presents an effective means of identifying bioactive molecules with cancer selective
antiproliferative activity. This approach, when applied to larger and more diverse sets of compounds with refined
drug-like properties, bears the potential of revealing both unknown cellular pathways globally impinging on p27
and novel leads for chemotherapeutics targeting a prominent molecular defect of human cancers.
Background
p27 is a cyclin-dependent kinase (CDK) inhibitor (CKI)
that controls cell proliferation, cell motility and apopto-
sis [1]. It regulates the progression of cells from G1 to S
phase by binding and inhibiting the cyclin E-CDK2
complex. A plethora of evidence has implicated downre-
gulation of p27 in prevalent human carcinomas [1]. For
example, downregulation of p27 is among the most fre-
quent non-genetic molecular alterations in prostate can-
cer (PCa) [2]. In this disease, low p27 expression is
correlated with a number of prognostic morphological
features [3] and with decreased survival [4]. In contrast,
ectopic expression of p27 can inhibit cell cycle progres-
sion in a human PCa cell line [5], suppress astrocytoma
growth in nude mice [6] and induce the death of breast
cancer cells [7]. Based on these findings, p27 has been
denoted as a tumour suppressor.
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complex [1]. It involves regulation at the level of tran-
scription, messenger (m)RNA translation [8] and protein
stability. The distribution among different cyclin-CDK
complexes [9], its sub-cellular localization [10] as well as
phosphorylation of several residues in p27 are important
mechanisms of control [11-13]. p27 levels are high in
quiescent cells and decrease rapidly upon mitogenic sti-
mulation. However, the cell cycle-dependent variations
in p27 levels are not reflected by similar changes in p27
mRNA [8,14]. Unlike traditional tumour suppressor
genes, the p27 gene rarely undergoes homozygous inac-
tivation in cancer cells [15-17], a finding that points
towards alternative mechanisms of p27 inactivation.
Many aggressive cancers display decreased p27 protein
levels in the presence of high p27 mRNA [18,19], sug-
gesting that p27 depletion is primarily a result of ectopic
proteolysis.
The p27 protein accumulates in cells when the ubiqui-
tin proteasome system (UPS) is inhibited [20]. This sys-
tem employs a cascade of enzymatic reactions that
covalently attach a ubiquitin chain to a substrate protein
[21], leading to the recognition by the proteasome for
degradation. Biochemical studies identified SCF
SKP2,a n
ubiquitin ligase complex that mediates phosphorylation-
dependent p27 ubiquitylation in vitro [13,22]. Two other
enzymes, KPC and PIRH2, have been also been impli-
cated as E3s for p27 [23-25]. Whereas SCF
SKP2 mediates
the degradation of nuclear p27 throughout S phase and
G2, KPC targets cytoplasmic p27 upon cell cycle entry
from G0 [23,25]; PIRH2 instead targets nuclear and
cytoplasmic p27 [24].
Considerable evidence suggests, however, that SKP2 is
the prominent regulator of p27 levels in cancer cells
[26]. SKP2 overexpression is frequent in human carcino-
mas devoid of p27 [27-32]. In addition, our own data
have shown that SKP2 overexpression in LNCaP pros-
tate cancer cells is sufficient to direct p27 ubiquitylation
and degradation [33]. Furthermore, transgenic expres-
sion of SKP2 in the mouse prostate causes low-grade
prostate carcinomas that coincide with p27 downregula-
tion [32]. Conversely, RNA interference (RNAi)-
mediated knockdown of SKP2 expression inhibits
tumour growth in a mouse transplant model [34]. These
findings validated p27 degradation pathways as promis-
ing cancer drug targets [35].
The complexity of p27 regulation presents consider-
able challenges to drug development because of the
potential for redundancies. Thus, it is not readily appar-
ent which enzyme involved in p27 regulation should be
targeted in order to effect sustained p27 accumulation
in cancer cells. In addition, pharmacological agents
active in an enzyme assay in vitro are not necessarily
bioactive in intact cells. Rather than targeting a
preselected component, we have developed a method
for the up-front identification of compounds that are
bioactive in restoring physiological levels of p27 in pros-
tate cancer cells. Using a validated cell-based assay, two
compounds, small molecule inhibitors of p27 depletions
(SMIPs) 001 and 004, were identified, which had the
desired activity. SMIPs restored p27 to physiological
levels, inhibited CDK2 activity and caused cell cycle
delay or apoptosis selectively in prostate cancer cells but
not normal cells.
Results
Generation and validation of an LNCaP-derived screening
cell line overexpressing SKP2
Prostate cancers typically display an inverse correlation
between the levels of p27 and SKP2 [29]. In contrast,
the commonly used human prostate cancer cell line
LNCaP, despite faithfully recapitulating many features of
human prostate cancer [36], expresses relatively high
levels of p27 but low levels of SKP2 when compared to
HeLa cells (Figure 1a). In order to mimic the situation
prevailing in primary prostate cancers, we created the
LNCaP derivative cell line, LNCaP-S14, which stably
overexpresses Myc-tagged SKP2 at six to eightfold
excess over endogenous SKP2, a manoeuvre that led to
maximal downregulation of p27 (Figure 1b). The same
pattern was apparent by immunofluorescence staining;
while nuclear levels of p27 are low in LNCaP-S14 cells,
nuclear SKP2 levels are highly elevated (Figure 1c).
We also determined whether known inhibitors of p27
degradation could upregulate p27 in LNCaP-S14 cells.
Upon normalization to the loading control actin, the
proteasome inhibitors MG132, epoxomycin and bortezo-
mib caused between 1.2 and 1.7-fold upregulation of
p27, while the CDK inhibitor roscovitine led to 1.5-fold
accumulation (Figure 1d). The induction of nuclear p27
by MG132 and roscovitine was also apparent by immu-
nofluorescence (Figure 1e).
Development of a high throughput screening assay to
score the level of nuclear p27
The immunofluorescence assay used in Figure 1c and 1e
was adapted to 384 well plate format. All parameters,
including the number of cells to be seeded, fixation,
blocking conditions, antibody concentrations and incu-
bation times with compounds were extensively opti-
mized using positive (proteasome and CDK inhibitors)
and negative (dimethyl sulfoxide; DMSO) controls,
resulting in the reliable protocol described in the Meth-
ods section. Representative images of LNCaP-S14 cells
treated with DMSO or roscovitine and stained with the
above protocol in 384 well plates are shown in Figure 1f.
In order to evaluate the performance of our assay to reli-
ably measure the percentage of p27 positive cells in a cell
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control reagent roscovitine. The Z’-factor measures the
variation and separation bands of an assay thereby provid-
ing a statistical measure of its quality. It takes into account
the dynamic range and variability of the positive and nega-
tive control measurements [37]. We determined a Z’-fac-
tor of 0.48 using the ImageXpress Micro and MetaXpress
software from Molecular Devices (CA, USA) and 0.60
using the Cell Lab IC100 and Cytoshop software from
Beckman Coulter (USA). Both values are deemed appro-
priate for a successful screen [37]. Figure 1g shows the sig-
nal-to-background ratios using both imaging platforms.
Primary screen
In order to assess the utility of the above protocol, we
performed a pilot screen of 7368 compounds (derived
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Figure 1 Characterization of the LNCaP-S14 screening cell line. (a) Basal levels of p27 and SKP2 were examined by immunoblotting in
LNCaP and HeLa cells. (b) Parental LNCaP cells as well as cells stably transfected with empty vector (P10) or Myc-SKP2 (LNCaP-S14) were
examined for the expression of p27 and SKP2 by immunoblotting. The numbers under each lane represent the tubulin normalized levels of p27
and SKP2 relative to untransfected LNCaP cells. (c) Basal levels of p27 and SKP2 in LNCaP and LNCaP-S14 were visualized by
immunofluorescence. Images were taken using a Nikon Eclipse E600 microscope at 60× magnification. (d) The levels of p27 and SKP2 were
analysed in total cell lysate from LNCaP-S14 cells treated with the proteasome inhibitors MG132 (20 μM), epoxomycin (1 μM) and bortezomib
(100 nM) or the CDK inhibitor roscovitine (20 μM) for 18 h. The numbers under each lane represent actin normalized levels of p27 and SKP2
relative to DMSO treated cells. (e) p27 and SKP2 staining in cells treated with the indicated compounds for 18 h. (f) Cells seeded in a 384 well
plate and treated with vehicle (dimethyl sulfoxide; DMSO) or roscovitine (20 μM) for 18 h were fixed and stained for p27. Images were obtained
using the ImageXpressMicro automated microscope (Molecular Devices) at 20× magnification. (g) The graph represents the percentage of p27
positive cells +/- standard deviations in LNCaP-S14 cells treated with DMSO or roscovitine and analysed with two imaging platforms (MetaXpress
and CytoShop) as described in the Methods section. Data are representative of three independent experiments.
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Page 3 of 18from a variety of different compound libraries, see
Methods) in duplicates for a total of 44 384-well plates.
LNCaP-S14 cells were incubated with individual com-
pounds (final concentration varied between ~5 and
35 uM depending on the molecular weights of the com-
pounds) for 18 h, followed by fixation, staining, imaging
(automatic microscopy) and analysis as described in
Methods. We scored the percentage of cells positive for
p27 in each well relative to the vehicle control (DMSO).
Figure 2a shows the activity of positive control com-
pounds (yellow triangles), the negative control com-
pound DMSO (red squares), the non-specific staining
(blue diamonds) and small molecules derived from com-
pound libraries (blue circles) across all screening plates
(44 plates) prior to normalization. Negative controls
(DMSO) gave basal percentages of p27 positive cells
ranging between 2% and 13% while the positive control
roscovitine increased these populations up to 50%. As
expected, the average of ~320 well measurements per
plate - that is, the percentage of p27 positive cells in
wells treated with individua lc o m p o u n d s-w a ss i m i l a r
to the percentage of p27 positive cells in the negative
control (DMSO), indicating that most compounds tested
were inactive in causing p27 accumulation (Figure 2a).
Normalization of raw data for 7368 compounds was
performed by calculating Z scores, which represent the
number of standard deviations by which a signal for a
g i v e nc o m p o u n dd i f f e r e df r o mt h em e a ns i g n a lo ft h e
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Figure 2 Assay data from the primary screen. (a) The graph represents the mean percentages of p27 positive cells detected across all wells
in each of the 44 screening plates (blue circles). The data are further stratified by treatment: Red squares indicate the mean percentages
obtained with the negative control (dimethyl sulfoxide; DMSO), yellow triangles indicate the mean percentages obtained with the positive
control (roscovitine). Blue diamonds indicate the mean percentages obtained by staining without the primary p27 antibody (non-specific
background staining). (b) Sum Z-scores. The heat map represents the sum of Z-scores from each well in 22 plates. DMSO (negative control) was
added to column 1, roscovitine (positive control) to column 2, and in some cases to columns 22 and 23, and the non-specific staining was
performed in columns 23 and 24. (c) Heat map of a representative screening plate showing potential hits based on their Z score. The first
column on the plate contained the negative control DMSO, the second column contained the positive control agent roscovitine, and columns
23 and 24 were stained without the primary p27 antibody (non-specific background staining). The well marked with a black square was
identified as containing a false positive compound, whereas the red circle indicates a potential hit. A representative micrograph from well L12
(potential hit) is shown to the right.
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Page 4 of 18entire plate [38]. It excludes control measurements alto-
gether under the assumption that most compounds are
inactive and can serve as intrinsic controls. The
summed Z scores for one set of duplicates (22 plates)
showed clear separation between the positive control
compound roscovitine (column 2) and the non-specific
staining (cells treated with DMSO or stained with sec-
ondary antibody only, columns 23 and 24; Figure 2b). In
addition, most summed Z scores had values similar to
the negative controls (DMSO), indicating that we did
not incur errors caused by plate position of compounds.
This was further evaluated by visualizing every plate as
a heat map of individual Z scores. As shown in the
example of a single plate in Figure 2c, potential hits
were randomly distributed over the plate (green and yel-
low positions). The analysis also identified several false-
positive compounds with very high Z scores, namely
known DNA binding compounds of red colour (doxoru-
bicin and derivatives, crystal violet, homidium bromide,
propidium iodine, pararosalinine pamoate).
Results of the primary screen
In the initial primary screen, we identified 249 com-
pounds that increased the percentage of p27 positive
LNCaP-S14 cells. Upon manual examination of micro-
scopic images, 21 duplicate compounds (occurring in
more than one library), seven obvious false positives
(DNA stains) and 45 compounds with low quality stain-
ing (few cells left in well, background, indiscriminate
whole cell staining) were sorted out. This resulted in a
list of 176 candidates (Additional File 1, Supplementary
Table 1) with sixty compounds classified as strong (Z
score > 5), 58 as medium (Z score 3-5) and the remain-
der as weak (Z score 2-3; Figure 3a). At a Z score of 3,
a compound has a theoretical probability of 0.0013 of
being a false positive hit.
A number of experimental and clinically used che-
motherapeutics such as camptothecin, thapsigargin, 17-
N-allylamino-17-demethoxygeldanamycin, mitomycin C
and etoposide were identified (Additional File 1, Supple-
mentary Table 1). The PI3 kinase inhibitor Wortmannin
also scored positive, a finding that is consistent with the
known role of the PI3K/AKT pathway in the downregu-
lation of p27 through SKP2 [39]. We further validated
some of the known bioactive compounds by immuno-
fluorescence staining and immunoblotting (Figure 3b
and 3c; data not shown).
Secondary screening
The one hundred and nine most potent compounds
(Z ≥ 3) were selected for confirmation by secondary
screening using the primary screening assay. After statis-
tical analysis, 60 compounds were still considered posi-
tive hits (Figure 3d). It is well established that
compounds with high activity in the primary screen will
appear less potent in the secondary screen because of a
statistical effect known as ‘regression towards the mean’
[38]. Thus, weaker hits often fail to validate in the sec-
ondary screen due to random measurement error. Addi-
tional counter screening for autofluorescence identified
another false-positive (pyrvinium pamoate).
Thirty-seven of the 60 validated compounds had
known biological activity (for example, inhibitors of pro-
tein synthesis and topoisomerase activity, antibiotics and
antihelmintics). Of the remaining 23 compounds, none
of which had known bioactivity, 20 were prioritized for
further characterization based on features of their che-
mical structures. These compounds were denoted small
molecule inhibitors of p27 depletion, SMIPs.
Activity and specificity of SMIPs in p27 accumulation
Sixteen of the 20 SMIPs were obtainable as powders
from commercial sources. The identity and integrity of
all compounds was confirmed by high-performance
liquid chromatography (HPLC) and mass spectrometry
(data not shown). SMIPs were retested for activity in a
dose-response experiment using the primary screening
assay. Thirteen out of 16 purchased SMIPs induced a ≥
twofold increase in the percentage of p27 positive cells
at the maximal dose with the remaining compounds
having lower activity (data not shown). SMIP014 was
identified as an additional false positive at this step (data
not shown).
Table 1 Cytotoxicity was analysed by MTT assay in
LNCaP-S14 and IMR90 cells treated with increasing
concentrations (0.01 - 40 μM) of the respective small
molecule inhibitors of p27 depletion (SMIPs) for 72 h
LNCaP-S14 IMR90
MG132 0.379 0.445
Thapsigargin 0.0078 0.031
SMIP001 4.63 > 20
SMIP002 11.09 > 40
SMIP003 15.92 65.36
SMIP004 1.09 > 20
SMIP005 1.71 17.38
SMIP006 6.63 NT
SMIP009 > 40 > 40
SMIP011 > 40 ~ 40
SMIP012 4.59 ~ 10
SMIP013 18.15 ~ 20
SMIP015 13.02 ~ 20
SMIP016 14.63 4.41
SMIP017 23.73 > 40
SMIP018 > 40 > 40
SMIP019 NT ~ 40
NT: not tested.
The data in the table represents the IC50 (μM).
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determined by immunoblotting (Figure 4a and 4b),
although the effects were generally weaker (~twofold at
40 μM). While seemingly small, such an increase is bio-
logically significant because p27 levels do not vary more
than two- to threefold during a normal cell cycle ([40]
and our own unpublished observation). This apparent
discrepancy between the immunofluorescence and
immunoblotting data, which we had encountered pre-
viously during assay development (with positive control
compounds roscovitine and MG132; Figure 1c and data
not shown), is explained by the different metrics of the
assays: While the immunofluorescence assay determines
the percentage of cells with nuclear p27 staining above
a threshold determined by staining with secondary anti-
body alone, the immunoblotting assay measures the
total amount of p27 that can be extracted from a cell
population (no threshold).
Further prioritization of the remaining 15 SMIPs was
achieved by counter screening against another unstable
prostate tumour suppressor (NKX3.1) [41,42]. In order
to address target specificity, LNCaP cells stably overex-
pressing NKX3.1 fused to yellow fluorescent protein
(NKX3.1-YFP) were used. Cells were treated with a sin-
gle concentration (40 μM) of SMIPs in 384-well plates
and analysed by automated microscopy (see the Meth-
ods section). The Z’ factors for this assay, as determined
by positive and negative controls, were between 0.62
(epoxomycin) and 0.67 (MG132), while the signal-to-
background ratio was five in both cases. Although some
SMIPs (005, 006, 016) caused a ~twofold increase in the
percentage of NKX3.1 positive cells, the effect was
subtle in comparison to proteasome inhibitors (~five-
fold; Figure 4c) and could not be confirmed by immu-
noblotting (data not shown). Likewise, when the
expression of endogenous NKX3.1 was evaluated in
DU145, another prostate cancer cell line with very low
levels of NKX3.1, none of the SMIPs scored positive
(data not shown). The minor effects of some SMIPs in
the NKX3.1-YFP fluorescence assay were most likely an
artifact of compound autofluorescence at the wavelength
used to excite YFP.
We also determined the effect of SMIPs on a HeLa
cell line stably expressing p27 fused to firefly luciferase
(p27-luc) [40,43]. While proteasome inhibitors led to an
increase in p27-luc expression, which was readily appar-
ent by luciferase assay (Figure 4d) and immunoblotting
(data not shown), none of the SMIPs were active. This
finding suggests a certain degree of cell type specificity
of SMIP action.
SMIPs inhibit cell growth and induce cell death
Since p27 can drive cell cycle arrest, senescence, and
apoptosis [7,44,45], we assessed the effect of SMIPs on
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Figure 3 Primary screening results. (a) Summary of the primary screen in LNCaP-S14 cells. From 7368 compounds analysed in duplicates, 176
were positive in the primary screening. They were classified according to their Z-score as strong (Z > 5), medium (Z = 3-5) and weak (Z = 2-3).
(b) Effect of increasing concentrations (18 h treatment) of the positive screening hit camptothecin (CPT) on p27 and SKP2 levels in LNCaP-S14
cells by regular immunofluorescence and immunoblotting (c). (d) 109 strong and medium compounds were selected for secondary screening.
Of those 60 compounds were still positive.
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IMR90 normal human fibroblasts were exposed to
increasing concentrations of SMIPs for 72 h and scored
using the MTT assay followed by calculation of IC50
values (concentration required for 50% inhibition)
(Table 1). Whereas SMIP012 and 016 were moderately
toxic in normal fibroblasts, SMIPs 001 and 004 showed
substantial cancer cell specificity being at least five
times more potent in LNCaP-S14 than in IMR90 cells.
Although SMIP005 also showed good cell type selectiv-
ity, it was excluded at this point due to structural fea-
tures that suggested potential unspecific reactivity with
cellular macromolecules. Based on their apparent cancer
cell specificity and their chemical structures, SMIPs 001
and 004 were selected for additional studies.
SMIPs induce dose-dependent accumulation of p27
and p21
Figure 5a shows the chemical structures of the two
compounds. We next confirmed the accumulation of
p27 upon treatment with 40 μMS M I P 0 0 1a n d0 0 4i n
LNCaP-S14 cells (Figure 5b). The CKI p21, which was
described as another ubiquitylation target of SKP2 [46],
was also upregulated by SMIPs (Figure 5b). The effects
on p27 and p21 were also observed with the CDK inhi-
bitor roscovitine. Interestingly, SMIP004 caused a
decrease in the levels of both the endogenous and the
exogenous, stably expressed SKP2. In contrast, treat-
ment of normal human fibroblasts with SMIPs did not
affect p27 or p21 levels (see below).
In order to evaluate the dose-response of the effect on
p27, LNCaP-S14 cells were treated with increasing con-
centrations of the respective SMIPs (5 - 40 μM), and
the percentage of cells with nuclear p27 was measured
by immunofluorescence and automated microscopy.
Both SMIPs led to a dose-dependent increase in p27
positive cells (Figure 5c). Dose-dependent increases in
p27 and p21 were also observed by immunoblotting
(Figure 5d). Whereas SMIPs 004 led to ~threefold
induction at 40 μM, SMIP001 was less active in this
experiment causing only a modest accumulation of p27
(30%-40%).
In order to begin to determine the mode of action of
SMIPs, we measured their effects on p27 protein stabi-
lity in a cycloheximide chase experiment. Whereas the
half-life of p27 was ~ 1.29 h in cells treated with
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Figure 4 Validation of prioritized small molecule inhibitors of p27 depletions (SMIPs). (a) Accumulation of p27 upon treatment with
SMIPs. LNCaP-S14 cells were treated for 18 h with the respective SMIPs (40 μM), DMSO (-) or the positive control MG132 (M). The data is
representative of three independent experiments. (b) Quantification of three independent immunoblotting experiments by film densitometry
and normalization to the loading control tubulin. (c) Target pathway selectivity was evaluated in LNCaP cells stably transfected with NKX3.1-YFP.
Cells were treated with 40 μM SMIPs for 18 h. YFP fluorescence was normalized to cell numbers and plotted relative to DMSO treated cells. The
graph represents the mean +/- standard deviation (SD) from 16 replicates. (d) Cell type specificity was evaluated by measuring the accumulation
of p27Luc in Hela_p27Luc cells. Luciferase activity was measured in total cell lysate from cells treated with 40 μM of the respective SMIPs. The
graph is representative of three independent experiments and shows the mean +/- SD from eight replicate measurements. Proteasome
inhibitors MG132 and epoxomycin were used as positive controls.
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Figure 5 Validation of SMIP001 and SMIP004. (a) Chemical structure of the two small molecule inhibitors of p27 depletions (SMIPs) identified
in the screen. (b) Cell lysates from LNCaP-S14 treated with 40 μM SMIPs for 24 h were analysed by immunoblotting. Roscovitine (R) was used as
positive control. The data shown is representative of two independent experiments. (c) LNCaP-S14 cells were treated with increasing
concentrations of SMIPs (5-40 μM) for 18 h followed by fixation and staining for p27. The graph represents data from 24 replicate wells per
concentration. (d) LNCaP-S14 cells were treated with SMIPs (5-40 μM) for 18 h and analysed by immunoblotting for the levels of p27 and p21.
(e) p27, p21 and SKP2 stability in LNCaP-S14 cells treated with 40 μM SMIPs for 18 h. Cycloheximide (CHX, 100 μg/mL) was added for the
indicated time points prior to preparation of cell lysates and immunoblot analysis. MG132 was used as positive control. The graphs represent the
quantification of p27, p21 and SKP2 levels relative to the zero hour time point. The data is representative of three independent experiments. (f)
LNCaP-S14 cells were treated with SMIP00s (40 μM) for 18 h followed by extraction of total RNA. The mRNA levels of p27, p21 and SKP2 were
quantified by quantitative polymerase chain reaction as described in the Methods section. All data was normalized to GAPDH and is expressed
as fold induction. The graph is representative of two independent experiments. (g) Total lysates of LNCaP-S14 cells treated with DMSO (-) or
SMIPs (20 and 40 μM) for 24 h were analysed by immunoblotting using anti-ubiquitin antibody. The proteasome inhibitors, MG132 (20 μM) and
bortezomib (100 nM) were used as positive controls. The blot is representative of two independent experiments.
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Page 8 of 18MG132 or SMIP004 increased p27 half-life to > 6 h
(Figure 5f). No effect on p27 stability was seen for
SMIP001. We also evaluated the stability of p21 and
SKP2 but did not see any effects of SMIPs on these pro-
teins. In summary, these data revealed a striking correla-
tion between the ability of SMIP004 to downregulate
SKP2 and to induce p27 stabilization. In contrast,
SMIP001 appears to regulate p27 and p21 primarily at
the level of mRNA expression (Figure 5f).
Since SMIP004 replicated the effect of MG132 on p27,
we tested whether it acts as a proteasome inhibitor.
Total cell lysate from LNCaP-S14 cells treated with 20
and 40 μM of the SMIPs were analysed by immunoblot-
ting with anti-ubiquitin antibody to assess the abun-
dance of polyubiquitylated proteins. None of the
compounds caused the accumulation of polyubiquity-
lated proteins that was readily seen with the proteasome
inhibitors MG132 and bortezomib (Figure 5g). Likewise,
none of the SMIPs inhibited the proteolytic activity of
purified 26S proteasomes toward fluorogenic peptide
substrates even when assayed at 40 μM concentration
(data not shown).
SMIPs cause inhibition of cellular CDK2 activity, G1 delay
and apoptosis in LNCaP-S14 cells
Since SMIPs robustly upregulated p27 and p21, we
asked whether this resulted in G1 delay. Indeed, SMIPs
001 and 004 induced a G1 delay with a concomitant
decrease in the S phase population (Table 2). We next
asked whether the cell cycle delay coincided with inhibi-
tion of CDK2, one of the major cellular target kinases of
p27 and p21. CDK2-cyclin complexes were immunopre-
cipitated from lysate of LNCaP-S14 cells treated with
DMSO, the CDK inhibitor roscovitine or SMIPs and
assayed for activity toward histone H1 in vitro.A sw i t h
roscovitine, application of SMIPs led to strong inhibition
of the CDK2 activity retrieved from cells (Figure 6a). In
order to test the possibility that SMIPs act like roscov-
itine as direct inhibitors of CDK2 kinase activity, SMIPs
were added to CDK2 complexes purified from untreated
cells. Unlike roscovitine, none of the SMIPs inhibited
CDK2 activity when added to the kinase reaction in
vitro (Figure 6b), indicating that the two SMIPs are not
kinase inhibitors.
We also evaluated the effect of SMIPs on the levels of
p27, p21 and cyclins E and A complexed with CDK2 by
coimmunoprecipitation. Both SMIP001 and 004 led to a
strong increase in the recruitment of p27 to CDK2,
while SMIP001 also slightly increased coprecipitation of
p21 (Figure 6c). SMIP004 also reduced the amounts of
cyclins E and A retrieved with CDK2 (Figure 6c). This
was paralleled by a marked downregulation of cyclins E
and A upon SMIP004 treatment (Figure 6c). A more
variable downregulation of cyclin A and CDK4 was
observed with SMIP001 (Figure 6e). Taken together,
these findings suggested that SMIP-induced inhibition
of CDK2 activity might be a combined consequence of
p27/p21 upregulation and cyclin E/A downregulation.
In order to determine the specific contribution of p27
and p21 to SMIP-induced cell cycle delay, we performed
siRNA-mediated knockdown studies. The depletion of
p21 and p27 led to a decrease in the G1 population of
untreated cells by 6 - 13 percentage points (Additional
File 2), a finding that indicates biologically significant
effects at the knockdown efficiencies achieved (~80%,
Figure 6e). Surprisingly, however, neither individual nor
combined knockdown of the two CKIs was able to abro-
gate SMIP-induced cell cycle delay (Figure 6d and Addi-
tional File 2). Likewise, CDK2 activity in SMIP-treated
cells was not rescued by knockdown of p27 and p21
(data not shown). Finally, neither the downregulation of
cyclins E and A nor that of CDK4 was consistently
affected by knocking down the CKIs, suggesting that
these effects of SMIPs probably account primarily for
their G1 delay activity.
In addition to G1 delay, treatment of LNCaP-S14 cells
with SMIPs for 24 h caused apoptosis as determined by
the cleavage of poly-ADP ribose polymerase (PARP,
Figure 6f and 6g). The apoptotic effect of SMIPs was
independently evaluated by measuring the amount of
Table 2 Cell cycle distribution in protein prostate cancer cell lines treated with 40 μM small molecule inhibitors of p27
depletion (SMIPs) for 24 and 48 h
LNCaP LNCaP
-S14
DU145 PC3 IMR90
Time SMIP G1 S G2 G1 S G2 G1 S G2 G1 S G2 G1 S G2
24 h DMSO 70.8 18.0 10.9 64.8 23.3 10.6 40.5 44.0 15.3 42.2 26.7 30.0 67.2 16.6 16.2
SMIP001 84.5 6.6 7.6 84.8 7.2 6.3 65.6 23.9 9.7 48.6 20.4 29.7 68.4 16.2 15.3
SMIP004 81.7 7.9 9.8 72.3 19.1 7.1 75.7 14.1 8.0 58.5 14.3 25.7 68.6 18.2 13.2
48 h DMSO 70.4 17.8 10.0 66.4 22.3 7.5 50.7 29.8 17.7 46.3 20.8 31.2 77.0 12.8 10.3
SMIP001 83.6 8.5 6.6 86.8 6.9 3.5 71.1 13.4 13.6 57.5 13.6 27.8 77.0 8.9 14.1
SMIP004 87.3 3.5 6.6 75.8 14.7 6.4 79.7 9.0 10.4 65.8 8.5 24.3 77.6 11.5 10.9
The data is representative of two independent experiments.
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Page 9 of 18cytoplasmic histone-associated DNA fragments. Cells
treated with 40 μM SMIP001 and 004 from 24 to 72 h
showed a three- to fivefold increase in the amount of
mono and oligonucleosomes, thus confirming the apop-
tosis-inducing activity of SMIPs.
Effects of SMIPs in other prostate cancer cell lines
A ss h o w ni nT a b l e2 ,S M I P sa l s oi n d u c e dr o b u s tG 1
delay in parental LNCaP cells as well as in two other
prostate cancer cell lines, DU145 and PC3. No such
effect was seen with HeLa cells or IMR90 fibroblasts. In
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Figure 6 Inhibition of CDK2 kinase activity and induction of apoptosis by small molecule inhibitors of p27 depletions (SMIPs).( a )
Histone H1 kinase assays were performed with CDK2 complexes immunopurified from LNCaP-S14 cells treated with 40 μM SMIPs for 24 h as
described in Methods. Roscovitine (R) was used as positive control. (b) Histone H1 kinase assays with CDK2 complexes immunopurified from
dimethyl sulfoxide (DMSO) treated LNCaP-S14 cells. The indicated SMIPs (20 μM) were added to the reactions. Roscovitine (R) was used as a
positive control for kinase inhibition in vitro. (c) Analysis of CDK2 complexes. Equal amounts of protein from LNCaP-S14 cells treated with DMSO,
SMIPs (40 μM) or roscovitine (R, 20 μM) were immunoprecipitated using an anti-CDK2 antibody as described in the Methods section. The levels
of co-precipitated cyclin E, cyclin A, p27, and p21 were evaluated by immunoblotting. (d) LNCaP-S14 cells were transfected with siRNAs for p27
and p21 as described in the Methods section and treated with DMSO or SMIPs (40 μM) for 24 h. The cell cycle distribution was analysed by flow
cytometry. The graphs represent the population of SMIPs-treated cells in G1 and G2 normalized to DMSO-treated cells for each siRNA. (e) Total
cell lysates from siRNA transfected cells were subjected to immunoblotting with the specified antibodies. The blots are representative of three
independent experiments. (f) Apoptosis was evaluated in total cell lysates from LNCaP-S14 cells treated with 40 μM SMIPs for 24 h. Poly ADP
ribosome polymerase (PARP) cleavage was visualized using an antibody that detects both full length (Fl) and cleaved (Cl) PARP. The blot is
representative of three independent experiments. (g) Quantification of mono and oligonucleosomes as indication of apoptosis. Lysates of cells
treated with DMSO or SMIPs (40 μM) for 24 h were obtained and analysed for cytoplasmic histone-associated DNA fragments as described in
the Methods section. The graph represents the DNA fragmentation enrichment factor ± standard deviation of two independent experiments.
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Page 10 of 18parental LNCaP cells, G1 delay correlated with an
increase in the levels of p27 and p21 as well as a down-
regulation of cyclins A and E and CDK4, which was par-
ticularly prominent with SMIP004 (Table 3 and Figure
7a). Unlike in SKP2 overexpressing LNCaP-S14 cells,
SKP2 was downregulated by both SMIP001 and 004 in
parental LNCaP cells, although the suppression was sub-
stantially greater with SMIP004 than 001 (Figure 7a).
Less pronounced effects on SKP2 were also observed in
PC3 and DU145 cells and in IMR90 fibroblasts. In con-
trast, when averaged over four independent experiments,
SMIPs had no consistent effect on p27 levels in PC3 and
DU145 cells, although a minor increase in p21 levels
was observed (Table 3) that coincided with a modest
reduction in the levels of cyclin A and CDK4 (Figure
7a). None of the latter effects were apparent either in
Table 3 Quantification of p27 and p21 protein levels in protein prostate cancer cell lines, HeLa and IMR90 cells
treated with 40 μM small molecule inhibitors of p27 depletion (SMIPs) for 24 h
LNCaP-S14 LNCaP PC3 DU145 HeLa IMR90
SMIP p27 p21 p27 p21 p27 p21 p27 p21 p27 p21 p27 p21
DMSO 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
SMIP001 1.9 ± 0.5 2.0 ± 0.6 1.5 ± 0.7 1.7 ± 0.6 1.3 ± 0.6 1.1 ± 0.5 1.1 ± 0.2 1.1 ± 0.3 1.1 ± 0.1 1.1 ± 0.2 1.0 ± 0.0 1.1 ± 0.0
SMIP004 2.4 ± 0.7 2.8 ± 0.7 2.1 ± 1.1 2.7 ± 0.1 1.1 ± 0.3 1.7 ± 0.9 1.3 ± 0.1 1.7 ± 0.5 1.1 ± 0.2 1.1 ± 0.1 1.2 ± 0.3 1.1 ± 0.0
MG132 1.5 1.9 ± 0.1 2.9 2.0 ± 1.0 4.1 ± 0.4 2.4 ± 0.1 3.1 2.2 ± 0.9 5.9 ± 1.7 0.9 ± 0.5 1.1 ± 0. 1
Bortezomib 1.8 2.1 2.5 ± 1.0 4.7 ± 1.4 1.7 ± 0.5 2.5 ± 0.4 1.3 ± 0.2 2.2 ± 0.8 1.8 ± 0.0 1.8 ± 0.4
The data is representative of at least four independent immunoblotting experiments.
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Figure 7 Effects of small molecule inhibitors of p27 depletion (SMIPs) in prostate cancer cell lines. (a) Prostate cancer cell lines, LNCaP,
PC3 and DU145 as well as HeLa and IMR90 cells were treated with vehicle (dimethyl sulfoxide; DMSO), SMIPs (40 μM) or the proteasome
inhibitors, MG132 (M, 20 μM) and bortezomib (B, 100 nM) for 24 h. The levels of the indicated proteins were evaluated by immunoblotting.
Asterisks denote an unspecific band. (b) The indicated cell lines were grown in soft agar and treated with vehicle (DMSO), SMIPs (40 μM), or
bortezomib (100 nM) with addition of fresh compounds in three-day intervals as described in the Methods section. The images are
representative of two independent experiments.
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Page 11 of 18HeLa or IMR90 cells. Despite a lack of induction of
apoptosis (PARP cleavage, Figure 7a) or overt cytotoxi-
city (Table 4), the SMIP-induced G1 delay of PC3 or
DU145 cells resulted in the same robust inhibition of
colony formation in soft agar as observed in LNCaP-S14
and parental LNCaP cells (Figure 7b).
Discussion
The intimate link between p27 depletion and cancers
deriving from the prostate and many other tissues ren-
ders pathways controlling p27 abundance attractive tar-
gets for the development of novel cancer therapeutics
[48]. At the same time, the complexity and apparent
redundancy of p27 regulatory pathways raises doubts as
to whether targeting a single enzyme or proximal regu-
lator can lead to sustained p27 accumulation in tumour
cells. Rather than screening for inhibitors of SCF
SKP2 or
other enzymes controlling p27, we have developed a
cell-based phenotypic screening system to identify com-
pounds that can modulate the p27 regulatory network
in cancer cells such that normal nuclear p27 levels are
restored. The platform was validated in a pilot screen
that identified two compounds of previously unknown
biological activity that efficiently reversed the depletion
of p27 in prostate cancer cells at low micromolar levels.
One of these compounds, SMIP004, increased p27 levels
by prolonging the half-life of the p27 protein. Therefore,
p27 depletion can be reversed by small molecules in
cancer cells overexpressing SKP2.
Whereas the cell-based format readily revealed
compounds that robustly modulated the screening end-
point - nuclear p27 levels - in intact cells, our pilot
screen also exposed the disadvantages of this approach,
namely that the molecular targets of SMIPs remain
unknown and that the modulated screening endpoint is
not necessarily causal to the ultimate cellular effects of
the compounds identified. For example, our RNA inter-
ference studies showed that neither p27 nor p21 were
required for SMIP-induced G1 delay in LNCaP-S14
cells. It is unlikely that inefficiency of the small
interfering RNA (siRNA)-mediated knockdown obscured
such a requirement for SMIP action, since depletion of
p21 and p27 decreased the fraction of cells in G1 thus
indicating that the knockdown efficiencies achieved here
were functionally consequential. In addition, p21 and
p27 levels in SMIP-treated knockdown cells were still
lower than or equal to the levels in untreated control
cells, suggesting that the minor accumulation of the
CKIs observed upon SMIP administration to knockdown
cells will be insufficient to cause a cell cycle arrest.
Two potential explanations can be offered to rationa-
lize the dispensability of p21 and p27 for SMIP-induced
G1 delay induced by SMIPs: First, it has been well
established that mouse embryonic fibroblasts lacking
p27 and p21 remain proficient in responding to negative
proliferation signals with cell cycle arrest because the
pocket proteins p107 and p130, which have CKI activity
themselves, compensate for the loss of the p27/p21
[49,50]. Secondly, SMIPs induced downregulation of
various positive cell cycle regulators, including cyclins E
and A and CDK4, which was fully maintained upon p27
and p21 knockdown. Thus, it is conceivable that the
combined effect of cyclin/CDK downregulation and
CDK inhibition by pocket proteins and other CKIs
accounts for SMIP-mediated cell cycle delay in the
absence of p27 and p21.
Although it appears that the compounds identified in
the present pilot screen caused p27 upregulation as a
secondary consequence of cell cycle delay, using nuclear
p27 accumulation as a screening endpoint readily
enabled the identification of cell permeable compounds
with antiproliferative activity. Notably, both SMIPs show
cancer cell selectivity as they induce cell cycle delay
and/or apoptosis in four different prostate cancer cells
but not in normal human fibroblasts. Moreover, they
inhibit colony formation in soft agar, which is a hall-
mark of the transformed phenotype of cancer cells and
considered a stringent surrogate for in vivo tumour for-
mation [51,52]. Finally, when applied to a more diverse
set of compounds with refined drug-like structures, our
screening platform may lead to the identification of
more potent and direct modulators of nuclear p27 accu-
mulation, similar in characteristics to the recently iden-
tified proteasome inhibitor argyrin A, which induces cell
cycle arrest and/or apoptosis that is strictly dependent
on p27 [45].
The high content screening platform described here
also enables chemical genetics strategies for the identifi-
cation of novel cellular pathways and targets impinging
on p27 - for example, the observation that SMIP004
strongly downregulates SKP2 appears significant with
regards to its mechanism of action. In a previous work
we demonstrated that SKP2 is a rate-limiting compo-
nent for p27 degradation in LNCaP cells [33]. A recent
Table 4 Cytotoxicity was assessed by MTT assay in
prostate cancer cell lines and normal fibroblasts treated
with increasing concentrations (0.01 - 80 μM) of the
respective small molecule inhibitors of p27 depletion
(SMIPs) for 72 h and 96 h
SMIP001 SMIP004
Cell line 72 h 96 h 72 h 96 h
LNCaP-WT 47.1 32.7 40 2.4
PC3 ~ 80 80 NE NE
DU145 ~ 40 32.5 NE NE
IMR90 40-80 40-80 NE NE
NE: No effect.
The data in the table represents the IC50 (μM). NE: No effect.
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tumour cell senescence that is dependent upon p27, p21
and the transcription factor ATF4 [53], which is an inte-
gral component of the unfolded protein response (UPR)
that is activated in response to endoplasmic reticulum
stress. Although the exact mechanism by which
SMIP004 downregulates SKP2 is presently unknown, we
have observed a robust activation of UPR signalling by
the compound (ERB and DAW, manuscript in prepera-
tion). A similar downregulation of SKP2 has been
noticed with the proteasome inhibitor bortezomib,
which is also an UPR inducer [54]. Mechanism of action
studies on SMIP004 are therefore beginning to suggest a
link between UPR-mediated downregulation of SKP2
and the accumulation of p27 (and perhaps p21). How-
ever, a substantial future effort will be required to deci-
pher the exact molecular targets of the compounds
identified here. Once those are revealed, target directed
high throughput screening campaigns could be initiated
t oi d e n t i f yam o r ed i v e r s es e to fc o m p o u n d sw i t h
improved potency toward p27 and clinical potential.
Conclusions
The results shown here provide proof-of-principle that
the cell-based screen we developed provides an effective
means of identifying bioactive molecules with cancer
selective antiproliferative activity. The advantage of a
cell-based screening format is, however, offset by the
limitation that the modulated endpoint is not necessarily
causal to the ultimate cellular effects of identified com-
pounds, thus requiring additional pathway deconvolu-
tion studies. Nevertheless, this approach can be applied
to larger and more diverse sets of compounds with
refined drug-like properties, revealing both unknown
cellular pathways globally impinging on p27 and novel
chemotherapeutic lead agents.
Methods
Compound libraries
NINDS, Prestwick Peakdale 1, Mixed Commercials,
Antimitotic, and Enamine and Known Bioactive Com-
pounds libraries were obtained from The Institute of
Chemistry and Cell Biology (ICCB) at Harvard Medical
School (MA, USA). Information about the libraries can
be found at http://iccb.med.harvard.edu.
SMIPs and other chemical compounds
SMIP001 to SMIP018 were purchased from Ryan Scienti-
fic (SC, USA). SMIP0019 was purchased from ChemDiv,
Inc (CA, USA). Roscovitine was purchased from Enxo
Life Sciences (formerly Biomol International; NY, USA),
bortezomib from LC Laboratories (MA, USA), cyclohexi-
mide (CHX) and camptothecin from Sigma (MO, USA),
MG132 and epoxomicin from BostonBiochem (MA,
USA). All drugs were dissolved in DMSO and kept at
-80°C.
Antibodies
Anti-p27 antibody (610241, 1:5000 for immunoblotting
and 1:1000 for immunofluorescence) was obtained from
BD Biosciences (NJ, USA). Anti-SKP2 (32-3300, 1:2000
for immunoblotting.) and anti-ubiquitin (13-1600,
1:2000) was from Zymed Laboratories (CA, USA). Anti-
SKP2 (sc-7164, 1:500 for immunofluorescence), anti-
CDK2 (sc-163, 1:1000 for immunoblotting, 2 μg/500 mg
protein for immunoprecipitation) and anti-CDK4 (sc-
260, dil 1:500) from Santa Cruz Biotechnology, Inc (CA,
USA). Antibodies for Cyclin E Ab-2 (clone HE12, dil
1:200) and Cyclin A Ab-6 (clone 6E6, dil 1:100) from
Thermo Scientific (CA, USA). Anti-p21 (2947, 1:2000)
and anti-PARP (9542, 1:1000) were from Cell Signaling
Technology (MA, USA). Anti-Tubulin (T5168, 1:5000)
was from Sigma Life Science. Anti-Actin (69100,
1:20000) was from MP Biomedicals, LLC (CA, USA).
HRP Donkey anti-mouse IgG (715-035-150, 1:5000) and
HRP Donkey anti-rabbit IgG (711-035-152, 1:5000) was
obtained from Jackson ImmunoResearch Laboratories
(PA, USA).
Creation of the LNCaP-S14 cell line and culture conditions
Parental LNCaP cells were stably transfected with a
plasmid driving the expression of Myc epitope-tagged
SKP2 or empty vector (pcDNA3). Briefly, 5 x10
6 cells
were transfected with 20 μg of each plasmid using Lipo-
fectamine 2000 reagent (Invitrogen, CA, USA) following
the manufacturer’s protocol. Cells were selected in 600
μg/mL geneticin (G418) until individual colonies were
visible. Colonies were picked, passed to 24 well plates
and expanded. The levels of p27 and SKP2 were
analysed by immunoblotting as described below.
LNCaP-S14 (positive clone for SKP2 overexpression),
LNCaP-P10 (vector control cell line), LNCaP (parental
cell line), PC3 and DU145 cells were maintained in
RPMI supplemented with 10% fetal bovine serum and
5% penicillin/streptomycin solution. IMR90 and HeLa
cells were maintained in DMEM containing 10% fetal
bovine serum, 5% penicillin/streptomycin and 4 mM
glutamine. Cells were grown as a monolayer in a humi-
dified incubator at 37°C and 5% CO2.
Immunofluorescence assay on cover slips and in 384 well
plates
The screen relies on the detection of differences in the
levels of endogenous p27 by immunofluorescence.
LNCaP-S14 cells were seeded at a density of 100,000
cells onto 15 mm glass cover slips and allowed to attach
for 1 day. Cells were treated with vehicle (DMSO) or
positive controls (roscovitine, MG132) for 18 h. After the
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Page 13 of 18incubation, cells were fixed by the addition of 10% paraf-
ormaldehyde in phosphate buffered saline (PBS; final
concentration 4%) and incubated for 20 min at room
temperature (RT). Cells were permeabilized by washing
3 × 5 min with PBS, 0.1% Triton X100, followed by
blocking in 5% nonfat dry milk in PBS, 0.1% Triton X100
for 1 h at RT. Cells were incubated with 50 μl primary
antibody (anti-p27, 1:1000 in blocking buffer) for 1 h, fol-
lowed by one wash with blocking buffer. 50 μL of second-
ary antibody (Alexa Fluor 594 goat anti-mouse,
Invitrogen A11005, 1:200 in blocking buffer) was added
for 1 h. Cells were washed 3 × 5 min in PBS, 0.1% Triton
X100 and stained with Hoechst dye (1 μg/mL in PBS) for
2 min. Cells were washed twice in PBS and mounted for
imaging with a Nikon Type 120 inverted fluorescent
microscope using 60× magnification. Compounds used
as positive controls included MG132, epoxomycin and
roscovitine, while DMSO was used as negative control.
C e l l ss t a i n e dw i t hs e c o n d a r ya n t i b o d yo n l yw e r eu s e dt o
assess the non-specific (NS) staining background.
The above protocol was adapted to 384 well plates as
follows: 4000 LNCaP-S14 cells per well were seeded into
384-well plates (black with clear bottom) in 30 μL
RPMI, 10% fetal bovine serum (FBS). Nuclear p27 stain-
ing was done under the same conditions as above but
with reducing the volume of solutions to 20 μL/well for
10% para-formaldehyde in PBS, 30 μL/well for blocking
and wash solutions and 15 μL/well for primary and sec-
ondary antibody solutions and Hoechst dye. All liquid
handling was done with an eight-channel multidrop
liquid dispenser (Wellmate, OH, USA) and a wand
aspirator (VP Scientific, CA, USA; VP-186L). After
staining, plates were sealed and stored in the dark at
4°C until scanning.
Images acquisition and analysis
Images from 384 well plates were acquired by using the
ImageXpress Micro inverted epifluorescent automated
microscope (Molecular Devices, CA, USA) at dual wave
length to detect Hoechst and p27. The microscope was
equipped with the Photometrics CoolSNAP ES digital
CCD camera and an automated objective and filter cube
changers. Two images per well at a 20× magnification
were obtained at each wave length.
Images were analysed with the MetaXpress cellular
imaging analysis software using the cell scoring module.
Cells were scored positive for Hoechst, if the integrated
pixel intensity was 210-fold above local background and
positive for p27 when staining was 30-fold above back-
ground (signal obtained with secondary antibody).
MetaXpress processing of the raw images provided
quantitative measures of the total cell number and the
number of p27 positive cells in a given field. The data
from both images of each well were combined to get a
single number of positive cells. The percentage of posi-
tive cells was calculated relative to the total number of
cells. Background correction was done by subtracting
the number of p27 positive cells in wells stained with
secondary antibody only.
The staining protocol was also evaluated using
another imaging and software package, the Cell Lab
IC100 and Cytoshop software (Beckman Coulter, CA,
USA). Minor changes were introduced to the protocol:
The cell number was reduced to 3000/well and the sec-
ondary Alexa Fluor 568 goat anti mouse antibody was
diluted 1:500 in blocking buffer. Four images per well
were taken using 10× magnification with a numerical
aperture of 0.25 and a camera binning of 2 × 2. A man-
ual threshold was established by comparison of the total
nuclear intensity in the positive control and the total
intensity obtained in cells stained with the secondary
antibody only (unspecific staining) and/or the vehicle
control (DMSO). Processing of the raw images provided
quantitative measures of the total cell number and the
number of p27 positive cells in a given field.
Z’-factor calculation: This parameter was used to
assess the quality of the assay in the HTP optimization
(HTP Company, CA, USA) [37]. In three independent
experiments, LNCaP-S14 cells were seeded in 384 well
plates followed by treatment with 0.3% DMSO (192
wells, negative control) or 20 μM roscovitine (192 wells,
positive control) for 18 h. The percentage of p27 posi-
tive cells was determined as described above and the Z’
factor calculated from 576 replicates (each condition) as
follows: Z’=1 -( 3 S D + +3 S D -)/(Ave+ -A v e -), where SD+
is the standard deviation for the positive control, SD-
the standard deviation for the negative control, Ave+ the
average for the positive control and Ave- is the average
for the negative control [37].
Primary screening
The cell-based screen was performed at the Institute of
Chemistry and Cell Biology, Harvard Medical School,
using libraries of uncharacterized compounds (Peakdale
1, Mixed Commercials, Antimitotic and Enamine, total
of 4888 compounds) plated in 5 mg/mL stock solutions
in DMSO, the NINDS library (1040 compounds, 10 mM
i nD M S O ) ,t h eP r e s t w i c kL i b r a r y( 9 6 0c o m p o u n d s ,
2 mg/mL) and a library of 489 known bioactive com-
pounds (plated at 5 mg/mL, 1.1 mg/mL, and 0.25 mg/
mL in DMSO) for a total of 7638 compounds. LNCaP-
S14 cells were seeded onto 384 well plates as described
above. Compound stocks (100 nL) were pin-transferred
using a robot-controlled stainless-steel pin array, result-
ing in a 300-fold-dilution (5 to 35 μM final screening
concentration, depending on individual compound
molecular weight) followed by incubation for 18 h. All
compound plates were screened in duplicates. Each
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(roscovitine, 20 μM), eight negative controls (DMSO,
0.3%) and eight wells of cells treated with 0.3% DMSO
and stained only with secondary antibody (non-specific
staining). Staining of p27, imaging and analysis was per-
formed as described above. Potential hits were classified
according to their Z score. The Z score is a simple and
widely known normalization method calculated as fol-
lows: Z = Xi -X / S x,w h e r eX i is the raw measurement
on the ith compound, X and Sx are the mean and the
standard deviation, respectively, of all measurements
within each plate [38]. Potential hits were classified as
weak if their Z score was between 2 and 3, medium if
the Z score was between 3 and 5 and strong if the Z
score was greater than 5.
Counter screening
Target specificity was analysed using LNCaP cells stably
expressing the homeobox transcription factor NKX3.1
f u s e dt oY F P .I nb r i e f ,4 0 0 0L N C a P - N K X 3 . 1 - Y F P( c l o n e
4A) cells were seeded in a 384 well plate and treated with
SMIPs for 18 h. Proteasome inhibitors were used as posi-
tive controls. Images from 384 well plates were taken
using the Cell Lab IC100 automated microscope (Beck-
man Coulter), and the percentage of cells positive for
NKX3.1-YFP was quantified using Cytoshop software
(Beckman Coulter). The percentage of NKX3.1-YFP posi-
tive cells was determined relative to DMSO treated cells.
Cell specificity was evaluated using HeLa cells stably
transfected with a p27-luciferase (p27Luc) construct
[43]. Briefly, HeLa-p27Luc cells were seeded in 96 well
plates and treated with 40 μM of the respective SMIPs
or positive controls (proteasome inhibitors). After incu-
bation for 18 h, cells were lysed using Cell Culture Lysis
Reagent from Promega (WI, USA) and luciferase activity
was determined by the Luciferase Assay System (Pro-
mega) using a Veritas microplate luminometer (Turner
Biosystems, CA, USA). Protein concentration was mea-
sured in a parallel plate using Bio-Rad Protein Assay
(Bio-Rad, CA, USA). Luciferase activity was normalized
against protein concentration and compared to the
activity recovered from DMSO-treated cells.
Immunoblotting
Total cell lysate from cells treated with vehicle (DMSO) or
compounds were obtained by incubating cells in lysis buf-
fer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Triton
X-100, protease inhibitors) for 15 min at 4°C. The super-
natant was collected by centrifugation and the amount of
protein was determined with a Bio-Rad protein assay (Bio-
Rad) using BSA as standard. Equal amounts of protein
were subjected to SDS-PAGE (4%-20% gels, Invitrogen)
and transferred to PVDF membranes. The membranes
were blocked with TBST (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.05% Tween-20) containing 5% non-fat
dry milk or bovine serum albumin (BSA) for 1 h at room
temperature, followed by incubation in primary antibodies
4°C overnight. Membranes were washed and incubated
with secondary antibodies conjugated to HRP (Jackson
ImmunoResearch Laboratories) for 1 h at room tempera-
ture. Signals were visualized using the ECL Western Blot-
ting Substrate (Pierce Biotechnology, IL, USA) according
to the manufacturer’s instructions. Membranes were
stripped using Restore™ Western Blot Stripping Buffer
(Pierce Biotechnology). Films were scanned and quantifi-
cation of the bands was performed using Image J software
http://rsbweb.nih.gov/ij/.
Co-immunoprecipitation
Total lysates of cells treated with vehicle (DMSO),
SMIPs or positive controls were prepared by incubation
in immunoprecipitation (IP) buffer (25 mM Tris-HCl,
pH 7.4; 150 mM NaCl, 0.5% Triton X-100, protease
inhibitors) for 15 min at 4°C. Upon centrifugation, the
supernatant was collected and the amount of protein
was determined with a Bio-Rad protein assay (Bio-Rad
Laboratories) using BSA as standard. Five hundred
micrograms of protein was adjusted to 1 mL with IP
buffer and incubated with 10 μL anti-CDK2 antibody
(sc-163, Santa Cruz Biotech) at 4°C for 3 h with con-
stant rotation, followed by addition of 100 μLp r o t e i n
G-sepharose beads (10% slurry) for 2 h. After four
washes for 5 min each with 1 mL IP buffer, beads were
resuspended in 2X-SDS Laemmli buffer, followed by
SDS-PAGE and immunoblotting.
In vitro kinase assay
Histone H1 kinase assays were performed as described in
reference [55]. Briefly, the total cell lysates from LNCaP-
S14 cells treated with the respective SMIP (40 μM) for 24
h were prepared in IP lysis buffer supplemented with
protease inhibitors followed by IP. Kinase reactions were
performed by adding histone H1 (1 μg) and 7.5 μCi
[g-
32P]ATP (800 Ci/mmol Perkin Elmer Life Sciences,
MA, USA) in kinase buffer (20 mM MgCl2,1 0m M
EGTA, 40 mM Hepes, pH 7). After incubation at 30°C
for 20 min, the reaction was stopped by adding 20 μL2 ×
SDS gel loading buffer. Samples were separated by elec-
trophoresis, gels were stained and dried, followed by
exposure to X-ray film. DMSO was used as negative con-
trol and roscovitine (CDK2 inhibitor) as positive control.
Cytotoxicity assay
LNCaP-S14 (10,000 cells), PC3, DU145 or IMR90 cells
(5000 cells) were seeded in 96-well plates and treated
with increasing concentrations of the respective SMIPs
for 72 h. Cell viability was assessed using the MTT cell
proliferation assay (ATCC
®, Middlesex, UK) according
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using the BioDataFit 1.02 software http://www.chang-
bioscience.com/stat/ec50.html.
Determination of protein half-lives by cycloheximide
chase
LNCaP-S14 cells were treated with SMIPs (40 μM) for
18 h followed by the addition of 100 μg/mL cyclohexi-
mide (CHX). Cell extracts were obtained as described
above at different times after CHX addition. Protein
lysate was subjected to SDS-PAGE and immunoblotting
f o rp 2 7 ,p 2 1a n dS K P 2 .T u b u l i nw a su s e da sl o a d i n g
control. Protein half-lives were calculated using a web
based calculator http://www.1728.com/halflife.htm.
RNA isolation and quantitative polymerase chain reaction
(q-PCR)
Total RNA was isolated from LNCaP-S14 cells treated
with 40 μM SMIPs or vehicle (18 h) using the RNeasy
Mini Kit (Quiagen, CA, USA), followed by first-strand
cDNA synthesis using Omniscript
® Reverse Transcrip-
tion (Quiagen). Real-time PCR analysis was performed
on the Stratagene Mx3000p detection system (Strata-
gene, Agilent, CA, USA) using the SYBR Green PCR
Master Mix (ABI, CA, USA) at the Microarray and q-
PCR Facility of the Sanford-Burnham Medical Research
Institute. The primers used were:
5’-ACTGCAGAGACATGGAAGAG-3’ and 5’-
ATGCGTGTCCTCAGAGTTAG-3’ for p27 (to amplify a
region from nucleotides 608 to 852); 5’-CGATG-
GAACTTCGACTTTG-3’ and 5’-GGGTACAAGACAGT-
GACAGG-3’ for p21 (to amplify a region from nucleotides
142 to 355); and 5’-TGAGCTGCTAAAGGTCTCTG-3’
and 5’-ATGTGCTGTACACGAAAAGG-3’ for SKP2 (to
amplify a region spanning from nucleotide 527 in exon
No. 2 to 739 in exon No.4). Briefly, reactions were done in
a2 5μL reaction volume of q-PCR mixture containing
2 μL of cDNA (40 ng) and 250 nM of each primer. Activa-
tion of the enzyme was done at 95°C for 10 min followed
by 40 cycles of amplification at 95°C for 30 s, 56°C for
1 min and 72°C for 30 s. All reactions were done in dupli-
cates and normalized using GAPDH as control. Primers
were design using Primer 3 http://frodo.wi.mit.edu/
primer3/ and synthesized by Valuegene, Inc, CA, USA.
Cell cycle analysis
Cells were exposed to SMIPs (40 μM) for 24 h and 48 h.
Cells were trypsinized, washed with PBS and suspended
in 600 μLP B S .C e l l sw e r ef i x e db ya d d i n g1 . 4m Lc o l d
absolute ethanol and kept at -20°C for at least 12 h.
After washing once with PBS, the cells were resus-
pended in 250 μL PBS containing 2.5 μgR N A s eAa n d
incubated for 45 min at room temperature. Staining was
done by adding 40 μg/mL of propidium iodine followed
by incubation for 15 min at room temperature. DNA-
bound fluorescence was read at 564 to 606 nm using
FACSort and FACSCanto flow cytometers (BD Bios-
ciences) at the Flow Cytometry Facility of the Sanford-
Burnham Medical Research Institute. Distribution of
cells in the different cell cycle phase was determined
with ModFit LT 3.2.1 or FlowJo 8.6 software. Aggregates
were excluded from the analysis manually using pulse
shape or identified by automated modelling in ModFit
LT.
Apoptosis assay
Apoptosis was measured using the Cell Death Detection
ELISA (Roche, Basel, Switzerland) following the manu-
facturer’s instructions. Briefly, LNCaP-S14 cells (0.1 ×
10
6) were seeded in 12-well plates and treated with
SMIPs (40 μM) for 24 h. Cells were collected in med-
ium, spun at 1000 rpm, and resuspended in 1 mL PBS
at the specified time points (day 1 to day 3). The cell
suspension was divided into two parts. The first half
was used for determination of cytoplasmic histone-asso-
ciated DNA fragments (ELISA), the second for protein
determination to normalize the ELISA data to the
amount of input protein.
siRNA transfection
LNCaP-S14 cells were seeded in 6 cm dishes or six-well-
plates coated with poly-lysine the day before transfec-
tion. 10-20 nM of siRNA was transfected using Dharma-
FECT 3 (Thermo Scientific) according to the
manufacturer’s instructions. Briefly, siRNAs were dis-
solved in siRNA suspension buffer (Quiagen) at 20 μM,
heated to 90°C for 1 min and incubated at 37°C for 1 h.
siRNAs were added to the DharmaFECT 3 reagent
diluted in Optimem media (1:100) and incubated for
20 min at room temperature. The mix was added to the
cells for 24 h. Treatment with SMIPs (40 μM) or vehicle
was carried on for another 24 h. Cells were obtained for
FACS or lysed for immunoblotting analysis as described
above. Untransfected cells as well as cells transfected
with non-specific siRNA were used as controls. Silen-
cer
® Negative Control siRNA No.1 from Ambion
(Applied Biosciences, CA, USA) was used as non-speci-
fic control siRNA. siRNA target sequences for p27 and
p21 synthesized by IDT (Integrated DNA Technologies
Inc, Iowa, USA) were as follows; p27 siRNA: AAG-
GUUGCAUACUGAGCCAAG, and p21 siRNA:
AACAUACUGGCCUGGACUGUU [56].
Soft agar assay
Agar Noble (Difco, MD, USA) was suspended at 6% in
water and autoclaved. A dilution 1:10 was made with
RPMI culture medium and added to six-well plates
(2 mL). We suspended 20,000 cells were in 0.5 mL
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0.5 mL of agar (0.6%) and poured immediately into a
six-well plate containing hardened bottom agar. Cells
were fed with fresh medium containing DMSO,
SMIP001, SMIP004 or bortezomib every third days.
Images were taken after 14 days using a Nikon Eclipse
E600 Microscope.
Additional material
Additional file 1: Supplementary Table 1. The table shows 176 small
molecule inhibitors of p27 depletion (SMIPs) identified in the primary
screening. Compounds were classified according to their Z factors as
strong (S), medium (M) or weak (W). Their position in the screening
(stock plate and well), simplified molecular input line entry specification
(SMILES), name and vendor are also listed. A column with known
biological actions is also shown for some compounds.
Additional file 2: Supplementary Table 2: The table shows the cell
cycle distribution of LNCaP-S14 transfected with small interfering RNA for
p27 and p21 and treated with SMIP004 (40 μM) as described in the
Methods section. Cell were analysed by flow cytometry and the
percentage of cells in the different phases of the cell cycle were
calculated.
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